EPISODE · Jun 18, 2018 · 8 MIN
Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms
from Journal of Clinical Oncology (JCO) Podcast · host Jonathan W. Riess
This podcast discusses the important risks and potential benefits of PD-1 immune checkpoint blockade in patients with thymic epithelial neoplasms. Read the related article "Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial" on JCO.org
NOW PLAYING
Risky Business: PD-1 Immune Checkpoint Blockade in Thymic Epithelial Neoplasms
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m